ArticleResearch square2026
Risk of extrapyramidal symptoms associated with antipsychotic drugs in children and adolescents: a systematic review and meta-analysis of double-blind randomised placebo-controlled trials.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Antipsychotic drugs are increasingly prescribed to children and adolescents (C&A) across a range of neuropsychiatric and neurodevelopmental disorders. Extrapyramidal symptoms (EPS) are well-established adverse effects of antipsychotics in adults, yet evidence in paediatric populations remains limited. This study aimed to quantify the risk of antipsychotic-related EPS in C&A and to explore potential moderating factors. Methods: This PRISMA-compliant systematic review and meta-analysis (PROSPERO; CRD42024564227) searched MEDLINE, Embase, and Web of Science from inception until the 6th of January 2026, for double-blind randomised controlled trials (RCTs) comparing antipsychotics with placebo in individuals aged < 18 years. EPS were assessed through either adverse event reporting or predefined thresholds on validated clinical rating scales and harmonised into a dichotomous outcome (presence vs. absence). Data were extracted by three pairs of independent researchers. Random-effects meta-analyses were conducted to estimate pooled risk ratios (RRs), alongside meta-regression and subgroup analyses examining potential moderators. Risk of bias was assessed using Cochrane Rob2. Results: Thirty-seven RCTs including 5,128 participants (3,141 receiving antipsychotics, 1,987 receiving placebo) were included. Exposure to antipsychotics was associated with a significantly increased risk of EPS compared with placebo (RR = 2.24, 95% CI = 1.71-2.93, p < 0.0001), corresponding to a number needed to harm of 7 (95% CI = 5-13). The highest risk estimates compared with placebo were observed for ziprasidone (RR = 3.59, 95% CI = 2.03-6.35, k = 3), risperidone (RR = 2.84, 95% CI = 1.89-4.28, k = 11), and aripiprazole (RR = 2.07, 95% CI = 1.12-3.82, k = 9). A higher proportion of female participants was associated with an increased risk of EPS (β = 0.0136, 95% CI = 0.0019-0.0254, p = 0.023), whereas longer treatment duration was associated with reduced risk (β=-0.0349, 95% CI = - 0.0573--0.0124, p = 0.002). No significant associations were observed for diagnosis, age, ethnicity, antipsychotic exposure, or non-antipsychotic concomitant medication use (all p > 0.05). Conclusions: Antipsychotic drugs are associated with EPS in approximately 1 out of 7 C&A with a more than twofold increased risk compared with placebo. The highest risk estimates were observed for ziprasidone, risperidone, and aripiprazole. Careful risk-benefit assessment, tailored prescribing, and systematic monitoring of EPS in routine paediatric clinical practice are warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.